Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer
(2022) Journal of Advanced Research — Vol. 40, p. 109-124 (2022)
Files
2021_Glorieux_J_Adv_Res.pdf
Postprint
Open Access - Adobe PDF
- 4.68 MB
Details
- Authors
- Abstract
- INTRODUCTION: Immunochemotherapy using PD-1/PD-L1 antibodies in combination with chemotherapeutic agents has become a mainstream treatment for cancer patients, but it remains unclear which drug combination would produce best therapeutic outcome. The purpose of this study is to compare two common chemotherapeutic drugs, gemcitabine and cisplatin, for their impact on the therapeutic efficacy of PD-1 antibody in K-ras-driven cancers known to overexpress PD-L1. METHODS: Both in vitro assays and syngeneic mouse tumor models were used in this study. Biochemical and molecular assays were used to determine the effects of drugs on T cell functions in cell culture models and mouse/human tumor tissues. Allograft tumor models with K-ras mutation were used to investigate the combination effect of gemcitabine or cisplatin with immunotherapy. Data of lung cancer patients with K-ras mutation treated with cisplatin and toripalimab were analyzed to evaluate the clinical relevance of the lab findings. RESULTS: Cisplatin and gemcitabine unexpectedly exert opposite effect on the therapeutic activity of PD-1 antibody in vivo . Gemcitabine antagonizes the therapeutic effect of PD-1 antibody due to its significant inhibition on CD8 + T cell infiltration, which was observed both in mouse tumor allografts and in human pancreatic cancer tissues. In contrast, cisplatin shows synergistic activity with PD-1 antibody by activation of CD8 + T cells through the DNA damage-mediated cGASSTING sensing mechanism, leading to increase of T cell infiltration and secretion of antitumor cytokines. Clinical data show that a combination of cisplatin with PD-1 antibody toripalimab could be effective in advanced lung cancer patients with K-ras mutation who failed prior therapies. CONCLUSIONS: Our study shows that a key factor in selecting chemotherapeutic agents for immunochemotherapy is the drug’s impact on T cell functions, and that cisplatinbased chemotherapy is an excellent choice for combination with immune checkpoint antibody to achieve favorable clinical outcome.
- Affiliations
Citations
Glorieux, C., Xia, X., You, X., Wang, Z., Han, Y., Yang, J., Noppe, G., de Meester de Ravenstein, C., Ling, J., Robert, A., Zhang, H., Li, S.-P., Wang, H., Chiao, P. J., Zhang, L., Li, X., & Huang, P. (2022). Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. Journal of Advanced Research, 40, 109-124. https://doi.org/10.1016/j.jare.2021.12.005 (Original work published 2022)